Announcement PDF ASX / MEDIA ANNOUNCEMENT 21 February 2014 INVION MD & CEO, DR GREG COLLIER, DISCUSSES 3M COLLABORATION WITH BRR MEDIA Clinical-stage drug development company Invion Limited (ASX:IVX) is delighted to invite investors to listen to Managing Director and CEO, Dr Greg Collier as he provides further background to this week’s announcement regarding Invion's collaboration with 3M Drug Delivery Systems for the development of its inhaled respiratory drug franchise. In this audiocast, Dr Collier discusses:  An overview of the collaboration with 3M Drug Delivery Systems to develop inhaled versions of respiratory drug assets INV102 (nadolol) and INV104 (zafirlukast), including the strategic benefits for Invion  What makes INV102 (nadolol) and INV104 (zafirlukast) unique as potential inhaled treatments for respiratory disease To access the audiocast, please visit this link: http://www.brr.com.au/event/120626 FOR MORE INFORMATION CONTACT Managing Director and CEO: Dr Greg Collier. P: 07 3295 0506 investor@inviongroup.com Media/ IR: Jane Lowe, Buchan Consulting P: 02 9237 2800 jlowe@buchanwe.com.au About INV104 (zafirlukast) Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance ofanaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. http://www1.astrazenecaus.com/pi/accolate.pdf. Zafirlukast is in the same class of anti-inflammatory drugs (i.e. anti-leukotrienes) as montelukast (Singulair®) - Merck’s largest selling drug until its patent expiry in August 2012. About Invion Limited Invion is a clinical-stage life sciences company focussed on the development of treatments for major opportunities in the inflammatory diseases market including asthma and COPD ($34B) and systemic lupus erythematosus (lupus) (to $4B). Invion has two drug assets in three FDA-regulated, phase II clinical trials currently underway in the US. INV102 (nadolol) is a beta blocker (beta adrenergic inverse agonist) currently used in the treatment of high blood pressure and migraine that is being repurposed to treat chronic inflammatory airway diseases (e.g. asthma and COPD). The US National Institutes of Health is funding Invion’s phase II asthma program in excess of USD$4M, and a second phase II trial in chronic bronchitis (smoking cessation) is also underway. INV103 (ala-Cpn10) is a modified naturally occurring human protein shown to reduce IL-6, a key marker in the chronic inflammatory disease, lupus. Invion Limited ABN 76 094 730 417 GPO Box 1557, Brisbane, QLD, 4001. P +61 7 3295 0500 F +61 7 3295 0599 www.inviongroup.com